The invention discloses compounds which irreversibly inhibit KRAS G12C mutation. A pharmaceutically acceptable salt and of the compound contains the compound or a salt thereof, and the invention also discloses an application of the compound or a salt and of the compound in the treatment KRAS G12C of a proliferative disease such as a sudden tumor.
-
(2021/11/26)
PYRROLOPYRIMIDINE COMPOUNDS
Compounds of formula (I) are A2B receptor antagonists: wherein Ri is optionally substituted aryl or an optionally substituted monocyclic heteroaryl group having 5 or 6 ring atoms; R2 and R3 are independently selected from
-
Page/Page column 33-34; 15
(2009/04/25)
More Articles about upstream products of 1131992-30-7